Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007 Jun 27;2(6):e542.
doi: 10.1371/journal.pone.0000542.

An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever

Anil Pandit  1 , Amit Arjyal, Jeremy N Day, Buddhi Paudyal, Sabina Dangol, Mark D Zimmerman, Bharat Yadav, Kasia Stepniewska, James I Campbell, Christiane Dolecek, Jeremy J Farrar, Buddha Basnyat
Affiliations
Randomized Controlled Trial

An open randomized comparison of gatifloxacin versus cefixime for the treatment of uncomplicated enteric fever

Anil Pandit et al. PLoS One. .

Abstract

Objective: To assess the efficacy of gatifloxacin versus cefixime in the treatment of uncomplicated culture positive enteric fever.

Design: A randomized, open-label, active control trial with two parallel arms.

Setting: Emergency Room and Outpatient Clinics in Patan Hospital, Lagankhel, Lalitpur, Nepal.

Participants: Patients with clinically diagnosed uncomplicated enteric fever meeting the inclusion criteria.

Interventions: Patients were allocated to receive one of two drugs, Gatifloxacin or Cefixime. The dosages used were Gatifloxacin 10 mg/kg, given once daily for 7 days, or Cefixime 20 mg/kg/day given in two divided doses for 7 days.

Outcome measures: The primary outcome measure was fever clearance time. The secondary outcome measure was overall treatment failure (acute treatment failure and relapse).

Results: Randomization was carried out in 390 patients before enrollment was suspended on the advice of the independent data safety monitoring board due to significant differences in both primary and secondary outcome measures in the two arms and the attainment of a priori defined endpoints. Median (95% confidence interval) fever clearance times were 92 hours (84-114 hours) for gatifloxacin recipients and 138 hours (105-164 hours) for cefixime-treated patients (Hazard Ratio[95%CI] = 2.171 [1.545-3.051], p<0.0001). 19 out of 70 (27%) patients who completed the 7 day trial had acute clinical failure in the cefixime group as compared to 1 out of 88 patients (1%) in gatifloxacin group(Odds Ratio [95%CI] = 0.031 [0.004 - 0.237], p<0.001). Overall treatment failure patients (relapsed patients plus acute treatment failure patients plus death) numbered 29. They were determined to be (95% confidence interval) 37.6 % (27.14%-50.2%) in the cefixime group and 3.5% (2.2%-11.5%) in the gatifloxacin group (HR[95%CI] = 0.084 [0.025-0.280], p<0.0001). There was one death in the cefixime group.

Conclusions: Based on this study, gatifloxacin is a better treatment for uncomplicated enteric fever as compared to cefixime.

Trial registration: Current Controlled Trials ISRCTN75784880.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Profile of the Trial.
The consort flow diagram showing the flow of participants through the trial.
Figure 2
Figure 2. Proportion of all patients still febrile.
Kaplan-Meier survival curve showing the proportion of all patients(ITT) still febrile through time.
Figure 3
Figure 3. Proportion of culture positive patients still febrile.
Kaplan-Meier survival curve showing the proportion of culture positive(PP) patients still febrile through time.
Figure 4
Figure 4. Proportion of relapse free patients.
Kaplan-Meier survival curve showing the proportion of relapse free patients in the culture positive population.
Figure 5
Figure 5. Proportion of overall failure free patients.
Kaplan-Meier survival curve showing the proportion of overall failure free patients in the culture positive population.
See this image and copyright information in PMC

References

    1. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid Fever. N Engl J Med. 2002;347:1770–1782. - PubMed
    1. Bahn M, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. Lancet. 2005;366:749–762. - PubMed
    1. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ. 2004;82:346–353. - PMC - PubMed
    1. Thaver D, Zaidi AK, Critchley J, Madni SA, Bhutta ZA. Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever). Cochrane Database Syst Rev. 2005;18:CD004530. - PubMed
    1. Woodward TE, Smadel JE, Ley HL, Green R, Mankikar DS. Preliminary report on the beneficial effect of chloromycetin in the treatment of typhoid fever. Ann Intern Med. 1948;29:131–134. - PubMed

Publication types

MeSH terms